Cybin Inc. Common Stock (HELP) Stock Price

HELPStock
$13.98+79.63%52W
Market Cap$1.02B
P/E
PEG Ratio
Div yield
Beta0.52

HELP Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)74.47%
Price vs S&P 500 (4W)55.81%
VGM Score89.27

HELP Earnings Surprise History

Q2 25-0.70est. -0.80
Q3 25-1.20est. -0.96
Q4 25-0.98est. -0.70
Q1 26-0.87est. -0.82
Q2 26-0.91est. -1.00

HELP Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
4.25
4.25
4.25
4.25

Industry Peers — Pharmaceuticals(571)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
HELPCybin Inc. Common Stock
A$13.98
LLYEli Lilly & Co.DBB$1233.66
JNJJohnson & JohnsonDCB$273.14
ABBVABBVIE INC.DCB$265.79
MRKMerck & Co., Inc.DCA$156.45
NVSNovartis AGCCC$159.98
AZNAstraZeneca PLCCBC$169.66
NVONovo-Nordisk A/SBCC$48.66
ABTAbbott LaboratoriesCCB$116.13
PFEPfizer Inc.CDC$28.57
VRTXVertex Pharmaceuticals IncDCB$552.85

About Cybin Inc. Common Stock

Helus Pharma is a clinical-stage biopharmaceutical company developing serotonergic agonists to treat mental health disorders, including depression and anxiety. The company's lead candidate, HLP003, is in Phase 3 development for adjunctive treatment of major depressive disorder. With operations across North America and Europe, Helus Pharma addresses an underserved market for innovative neuropsychiatric therapies.